{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:04:11Z","timestamp":1790327051201,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error\u2010prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological\/pharmaceutical care programme for children and their caregivers during OAT treatment (youngAMBORA). We now aimed to analyse the impact of the youngAMBORA care programme on medication safety by assessing (1) patient\u2010reported outcomes (PROs) and (2) medication errors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Depending on the intended OAT treatment duration, the youngAMBORA care programme included three or four consultation sessions starting at therapy initiation (Week 0) and using developed information material. Validated questionnaires were used to record PROs (e.g., knowledge [Satisfaction with Information about Medicines Scale, SIMS, primary outcome] and side effects [Ped\u2010PRO\u2010CTCAE\u00ae]). Advanced medication reviews were conducted in every consultation session, and medication errors were systematically categorized (e.g., PCNE V9.1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We counselled 54 patients treated with 61 OAT. The most frequently prescribed OAT was 6\u2010mercaptopurine (14\/61; 23%). Knowledge about the OAT improved significantly between Week 0 at OAT initiation and Week 1 (SIMS total score 8.1\u2009\u00b1\u20094.2\n                      <jats:italic>vs<\/jats:italic>\n                      . 15.8\u2009\u00b1\u20091.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.0001). On average, patients and caregivers reported 2.6 OAT\u2010related side effects per patient, with gastrointestinal symptoms (i.e., \u2018nausea\u2019) being most frequent and severe. Fifty\u2010six OAT\u2010related medication errors were detected (mean 1.0 per patient), and of these, 84% (47\/56) were completely resolved.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The youngAMBORA care programme improved caregivers' knowledge about OAT, enabled structured monitoring of patient\u2010reported side effects and facilitated the identification and resolution of medication errors during paediatric OAT treatment to optimize medication safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70816","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:20:14Z","timestamp":1790324414000},"source":"Crossref","is-referenced-by-count":0,"title":["Patient\u2010reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8024-2839","authenticated-orcid":false,"given":"Phyllis","family":"Lensker","sequence":"first","affiliation":[{"name":"Pharmacy Department Universit\u00e4tsklinikum Erlangen and Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Comprehensive Cancer Centre Erlangen\u2010EMN Universit\u00e4tsklinikum Erlangen  Erlangen Germany"},{"name":"Bavarian Centre for Cancer Research (BZKF)  Erlangen Germany"},{"name":"Department of Paediatrics and Adolescent Medicine Universit\u00e4tsklinikum Erlangen and Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-8503","authenticated-orcid":false,"given":"Lisa","family":"Cuba","sequence":"additional","affiliation":[{"name":"Pharmacy Department Universit\u00e4tsklinikum Erlangen and Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Comprehensive Cancer Centre Erlangen\u2010EMN Universit\u00e4tsklinikum Erlangen  Erlangen Germany"},{"name":"Bavarian Centre for Cancer Research (BZKF)  Erlangen Germany"},{"name":"Pharmacy Department Clinic Floridsdorf and Clinic Landstrasse, Vienna Healthcare Group  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-9212","authenticated-orcid":false,"given":"Frank","family":"D\u00f6rje","sequence":"additional","affiliation":[{"name":"Pharmacy Department Universit\u00e4tsklinikum Erlangen and Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Comprehensive Cancer Centre Erlangen\u2010EMN Universit\u00e4tsklinikum Erlangen  Erlangen Germany"},{"name":"Bavarian Centre for Cancer Research (BZKF)  Erlangen Germany"},{"name":"FAU NeW \u2013 Research Centre New Bioactive Compounds Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-7478","authenticated-orcid":false,"given":"Martin F.","family":"Fromm","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Comprehensive Cancer Centre Erlangen\u2010EMN Universit\u00e4tsklinikum Erlangen  Erlangen Germany"},{"name":"Bavarian Centre for Cancer Research (BZKF)  Erlangen Germany"},{"name":"FAU NeW \u2013 Research Centre New Bioactive Compounds Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-1676","authenticated-orcid":false,"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centre Erlangen\u2010EMN Universit\u00e4tsklinikum Erlangen  Erlangen Germany"},{"name":"Bavarian Centre for Cancer Research (BZKF)  Erlangen Germany"},{"name":"Department of Paediatrics and Adolescent Medicine Universit\u00e4tsklinikum Erlangen and Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1284"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102013\u2010305212"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.26"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12402"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6072"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023\u2010061281"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1950138"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2008.031179"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.204479"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014\u20100309"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012\u20102434"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0775"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315077"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100163"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221080445"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm\u20102015\u2010000716"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02669"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24463"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2219"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32525"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03088"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24099"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10428"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00694"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2009.00575.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102753.2009.01169.x"},{"key":"e_1_2_10_29_1","unstructured":"National Cancer Institute.Pediatric module of Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (Ped\u2010PRO\u2010CTCAE\u00ae).2024.https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895\u20104356(94)90192\u20109"},{"key":"e_1_2_10_31_1","unstructured":"Pharmaceutical Care Network Europe Association.Classification for drug related problems V9.1. 2003\u20132020.https:\/\/www.pcne.org\/upload\/files\/417_PCNE_classification_V9-1_final.pdf"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1423"},{"key":"e_1_2_10_33_1","first-page":"S1","article-title":"The concise guide to pharmacology 2025\/26","volume":"182","author":"Alexander SPH","year":"2025","journal-title":"Br J Pharmacol"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0001"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1043454216655983"},{"key":"e_1_2_10_36_1","article-title":"Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home","volume":"2003","author":"Johnson A","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183119"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/27527530221122685"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28216"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.077"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.04.020"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20609"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23158"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/27527530231206101"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.044"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3266"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm\u20102019\u2010001973"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010023\u201001626\u20105"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70816","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:20:17Z","timestamp":1790324417000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":47,"alternative-id":["10.1002\/bcp.70816"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70816","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"bcp.70816"}}